| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10969268 | Vaccine | 2012 | 5 Pages |
Abstract
⺠MenAfriVac is more immunogenic when compared to a licensed PS vaccine. ⺠MenAfriVac has an excellent safety profile when compared to PS vaccine. ⺠MenAfriVac has the potential to reduce the burden of NmA disease.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Siddhivinayak Hirve, Ashish Bavdekar, Anand Pandit, Sanjay Juvekar, Malini Patil, Marie-Pierre Preziosi, Yuxiao Tang, Elisa Marchetti, Lionel Martellet, Helen Findlow, Cheryl Elie, Varsha Parulekar, Brian Plikaytis, Ray Borrow, George Carlone,